$201 Million is the total value of Finepoint Capital LP's 30 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 30.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $18,890,712 | +22.7% | 331,416 | +9.7% | 9.41% | +76.6% | |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $18,106,544 | +8.7% | 1,489,025 | +12.3% | 9.02% | +56.5% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $17,620,176 | +22.6% | 145,357 | +15.9% | 8.78% | +76.6% |
| PRTA | Buy | PROTHENA CORP PLC | $16,853,725 | -22.2% | 349,300 | +10.1% | 8.39% | +12.0% |
| GLPG | Buy | GALAPAGOS NVspon adr | $15,846,668 | -4.2% | 458,659 | +12.7% | 7.89% | +37.9% |
| ASND | Buy | ASCENDIS PHARMA A/Ssponsored adr | $15,335,610 | +22.9% | 163,772 | +17.2% | 7.64% | +76.9% |
| SWTX | Sell | SPRINGWORKS THERAPEUTICS INC | $12,876,175 | -19.3% | 556,928 | -8.5% | 6.41% | +16.2% |
| CYTK | Buy | CYTOKINETICS INC | $12,717,676 | +5.6% | 431,693 | +17.0% | 6.33% | +52.1% |
| CERE | Buy | CEREVEL THERAPEUTICS HLDNG I | $12,297,821 | -21.5% | 563,345 | +14.4% | 6.12% | +13.1% |
| RVMD | New | REVOLUTION MEDICINES INC | $11,819,360 | – | 427,000 | +100.0% | 5.89% | – |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $11,598,565 | -42.8% | 556,553 | -34.3% | 5.78% | -17.7% |
| ARVN | Buy | ARVINAS INC | $9,912,308 | -2.9% | 504,700 | +22.6% | 4.94% | +39.7% |
| TVTX | Buy | TRAVERE THERAPEUTICS INC | $8,008,640 | -31.6% | 895,821 | +17.6% | 3.99% | -1.5% |
| MORF | Buy | MORPHIC HOLDING INC | $7,453,906 | -54.8% | 325,356 | +13.1% | 3.71% | -34.9% |
| RLAY | Buy | RELAY THERAPEUTICS INC | $7,324,017 | -16.9% | 870,870 | +24.1% | 3.65% | +19.7% |
| SOLID BIOSCIENCES INC | $2,422,353 | -51.9% | 961,251 | 0.0% | 1.21% | -30.8% | ||
| New | CALIDI BIOTHERAPEUTICS INC | $415,625 | – | 125,000 | +100.0% | 0.21% | – | |
| AACWS | ARES ACQUISITION CORP*w exp 02/02/202 | $333,611 | -17.4% | 504,706 | 0.0% | 0.17% | +18.6% | |
| BTWNW | BRIDGETOWN HOLDINGS LTD*w exp 09/30/202 | $304,300 | +37.1% | 895,000 | 0.0% | 0.15% | +97.4% | |
| CVIIWS | CHURCHILL CAPITAL CORP VII*w exp 02/29/202 | $168,784 | +120.0% | 548,000 | 0.0% | 0.08% | +211.1% | |
| CALIDI BIOTHERAPEUTICS INC*w exp 03/14/202 | $144,144 | +69.2% | 655,200 | 0.0% | 0.07% | +148.3% | ||
| COMPASS DIGITAL ACQUISITION CORP*w exp 09/29/202 | $101,271 | +48.0% | 459,906 | 0.0% | 0.05% | +108.3% | ||
| CCVIWS | CHURCHILL CAPITAL CORP VI*w exp 02/17/202 | $86,400 | -11.1% | 540,000 | 0.0% | 0.04% | +26.5% | |
| ROSSWS | ROSS ACQUISITION CORP II*w exp 02/01/202 | $49,023 | -34.1% | 439,666 | 0.0% | 0.02% | -7.7% | |
| CONCORD ACQUISITION CORP II*w exp 99/99/999 | $42,589 | +160.8% | 408,333 | 0.0% | 0.02% | +250.0% | ||
| SWIFTMERGE ACQUISITION CORP*w exp 12/13/202 | $34,594 | -28.0% | 490,000 | 0.0% | 0.02% | 0.0% | ||
| YS BIOPHARMA CO LTD*w exp 03/15/202 | $17,150 | -25.5% | 489,999 | 0.0% | 0.01% | +12.5% | ||
| MARBLEGATE ACQUISITION CORP*w exp 08/31/202 | $13,524 | -67.3% | 735,000 | 0.0% | 0.01% | -50.0% | ||
| Exit | CORSAIR PARTNERING CORP*w exp 07/06/202 | $0 | – | -334,666 | -100.0% | 0.00% | – | |
| CCVWS | CHURCHILL CAPITAL CORP V*w exp 10/29/202 | $0 | -100.0% | 612,000 | 0.0% | 0.00% | -100.0% | |
| HOME PLATE ACQUISITION CORP*w exp 09/30/202 | $0 | -100.0% | 690,000 | 0.0% | 0.00% | -100.0% | ||
| Exit | BILANDER ACQUISITION CORP*w exp 05/19/202 | $0 | – | -183,749 | -100.0% | -0.00% | – | |
| Exit | CONYERS PARK III ACQUISITION CORP*w exp 08/12/202 | $0 | – | -571,666 | -100.0% | -0.01% | – | |
| Exit | AFTERNEXT HEALTHTECH ACQUISITION CORP*w exp 99/99/999 | $0 | – | -366,666 | -100.0% | -0.01% | – | |
| BHC | Exit | BAUSCH HEALTH COS INC | $0 | – | -1,165,000 | -100.0% | -3.22% | – |
| CLVT | Exit | CLARIVATE PLC | $0 | – | -1,247,406 | -100.0% | -4.11% | – |
| CRNX | Exit | CRINETICS PHARMACEUTICALS IN | $0 | – | -797,527 | -100.0% | -4.97% | – |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -357,765 | -100.0% | -5.82% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -241,690 | -100.0% | -7.62% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| YPF SOCIEDAD ANONIMA | 17 | Q4 2018 | 32.7% |
| IRSA INVERSIONES Y REP S A | 15 | Q2 2018 | 10.1% |
| CHENIERE ENERGY INC | 14 | Q1 2018 | 29.9% |
| ALLY FINL INC | 13 | Q4 2017 | 42.0% |
| CRESUD S A C I F Y A | 13 | Q4 2017 | 4.0% |
| BRIDGETOWN HOLDINGS LTD | 9 | Q3 2023 | 0.2% |
| ARES ACQUISITION CORP | 9 | Q3 2023 | 0.2% |
| CHURCHILL CAPITAL CORP V | 9 | Q3 2023 | 0.2% |
| CHURCHILL CAPITAL CORP VII | 9 | Q3 2023 | 0.1% |
| CHURCHILL CAPITAL CORP VI | 9 | Q3 2023 | 0.1% |
View Finepoint Capital LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
View Finepoint Capital LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.